Abstract
Importance Post COVID-19 condition (PCC) is known to affect a large proportion of COVID-19 survivors. Robust study design and methods are needed to understand post-COVID-19 diagnosis patterns in all COVID-19 survivors, not just the ones clinically diagnosed with PCC.
Objective To assess which diagnoses appear more frequently after a COVID-19 infection and how they differ by COVID-19 severity and vaccination status.
Design We applied a case-crossover phenome-wide association study (PheWAS) in a retrospective cohort of COVID-19 survivors, comparing the occurrences of 1,649 diagnosis-based phenotype codes (PheCodes) pre- and post-COVID-19 infection periods in the same individual using a conditional logistic regression.
Setting Patients tested for or diagnosed with COVID-19 at Michigan Medicine from March 10, 2020 through May 1, 2022.
Participants 36,856 SARS-CoV-2-positive patients and 141,615 age- and sex-matched SARS-CoV-2-negative patients as a comparison group for sensitivity analysis.
Exposure SARS-CoV-2 virus infection as determined by RT-PCR testing and/or clinical evaluation.
Main Outcomes and Measures We compared the rate of occurrence of 1,649 disease classification codes in “pre-” and “post-COVID-19 periods”. We studied how this pattern varied by COVID-19 severity and vaccination status at the time of infection.
Results Using a case-crossover PheWAS framework, we found mental, circulatory, and respiratory disorders to be strongly associated with the “post-COVID-19 period” for the overall COVID-19-positive cohort. A total of 325 PheCodes reached phenome-wide significance (p<3e-05), and top hits included cardiac dysrhythmias (OR=1.7 [95%CI: 1.6-1.9]), respiratory failure, insufficiency, arrest (OR=3.1 [95%CI: 2.7-3.5]) and anxiety disorder (OR=1.7 [95%CI: 1.6-1.8]). In the patients with severe disease, we found stronger associations with many respiratory and circulatory disorders, such as pneumonia (p=2.1e-18) and acute pulmonary heart disease (p=2.4e-8), and the “post-COVID-19 period,” compared to those with mild/moderate disease.
Test negative patients exhibited a somewhat similar association pattern to those fully vaccinated, with mental health and chronic circulatory diseases rising to the top of the association list in these groups.
Conclusions and Relevance Our results confirm that patients experience myriad symptoms more than 28 days after SARS-CoV-2 infection, but especially mental, circulatory, and respiratory disorders. Our case-crossover PheWAS approach controls for within-person confounders that are time-invariant. Comparison to test negatives with a similar design helped identify enrichment specific to COVID-19. As we look into the future, we must be aware of COVID-19 survivors’ healthcare needs in the period after infection.
Question What patterns of clinical diagnosis tend to occur more frequently after a COVID-19 infection and how do they vary by COVID-19 severity and vaccination status?
Findings In a cohort of 36,856 COVID-19-positive patients, using a case-crossover phenome-wide association analysis that controls for within-subject confounders, we found symptoms such as anxiety disorder, cardiac dysrhythmias, and respiratory failure to be significantly associated with the “post-COVID-19 period.” Patients with severe COVID-19 were more likely to receive diagnoses related to respiratory conditions in their “post-COVID-19 period” compared to those with mild/moderate COVID-19. The landscape of phenome-wide association signals for the vaccinated group featured common chronic conditions when compared to the signals in the unvaccinated group.
Meaning Symptoms across multiple organ systems, especially in the mental, circulatory, and respiratory domains, were associated with the “post-COVID-19 period.” Characterization of post-COVID-19 diagnosis patterns is crucial to understand the long term and future healthcare burden of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research presented here was funded by the National Science Foundation (https://www.nsf.gov/) under grant DMS 1712933 (BM), the National Institutes of Health (https://www.nih.gov) under grant 5R01HG008773-05 (BM) and 5P30CA046592-30 (BM), and the Michigan Collaborative Addiction Resources & Education System (https://micaresed.org) under grant 1UG3CA267907-01 (BM). Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical review and approval were waived for this study due to its qualification for a federal exemption as secondary research for which consent is not required. Determination for exemption was made by the University of Michigan Medical School Institutional Review Board (study ID: HUM00180294).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analyzed during the current study are not publicly available due to MM privacy regulations.
